TABLE 1.
Patients characteristics | Cancer cohort (n = 39) | NonCancer cohort (n = 39) | P‐value | Solid tumors (n = 29) | Hematological tumors (n = 10) | P‐value |
---|---|---|---|---|---|---|
Age @ Covid‐19 diagnosis; median (range) | 73 (54‐95) | 76 (45‐96) | .3709 | 73 (54‐95) | 71 (55‐85) | .8353 |
< 65 yrs; n | 12 | 12 | 8 | 4 | ||
65‐75 yrs; n | 9 | 6 | 8 | 1 | ||
> 75 yrs; n | 18 | 21 | 13 | 5 | ||
Age at diagnosis of cancer; median (range) | 66 (45‐83) | — | 67 (48‐82) | 60 (45‐83) | .3276 | |
Active:nonactive disease; n | 24:15 | 15:14 | 9:1 | |||
f: m; n | 17:22 | 14:25 | .6439 | 13:16 | 4:6 | 1.0000 |
Nosocomial: community acquired | 14:20 | 16:17 | .6267 | 11:14 | 3:6 | .7401 |
Comorbidities | ||||||
Cardiovascular; n | 30 | 34 | .3768 | 23 | 7 | .6686 |
Diabetes; n | 5 | 9 | .3768 | 4 | 1 | 1.0000 |
Asthma/COPD; n | 3 | 11 | .0362 | 2 | 1 | 1.0000 |
CKD; n | 5 | 15 | .0183 | 4 | 1 | 1.0000 |
Rheumathologic disease; n | 3 | 3 | 1.0000 | 3 | 0 | .5558 |
Chronic liver disease; n | 1 | 3 | .6151 | 0 | 1 | .2564 |
≥ 2 organ involvements; n | 11 | 23 | .0115 | 8 | 3 | 1.0000 |
Sum of organ involvements; median | 1 | 2 | .0055 | 1 | 1 | .7314 |
History of smoking; n | 6 | 9 | .4998 | 6 | 0 | .1141 |
Cancer treatment in last 4 weeks | ||||||
Chemo/radio/immunotherapy; n | 9 | — | 6 | 3 | ||
Surgery only; n | 5 | — | 5 | |||
None; n | 25 | — | 18 | 7 | ||
Cancer treatment in last 4 y to 4 wks | ||||||
Chemo/radio/immunotherapy; n | 3 | — | 2 | 1 | ||
Surgery only; n | 2 | — | 2 | |||
None; n | 20 | — | 14 | 6 | ||
Type of cancer | ||||||
Uro‐gynecological; n | 16 | — | ||||
Lung; n | 5 | — | ||||
Head&neck/Skin; n | 5 | — | ||||
GI; n | 3 | — | ||||
Stage IV; n | 10 | — | ||||
Lymphoma/Myeloma; n | 7 | — | ||||
Leukemia/PNH; n | 3 | — |
Abbreviations: CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; n, number of patients; PNH, paroxysmal nocturnal hemoglobinuria.